Physician profile
Amanda Oblander
NPI 1114330099
$16,947.24
in general payments reported to CMS, 2019-2025
26 companies · $3,697 in 2025
The $3,697 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,066 · 2022: $2,096 · 2023: $4,110 · 2024: $4,979 · 2025: $3,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,591.63 |
| Education | $193.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,794.40 | 2021-2025 | |
| Janssen Biotech, INC. | $2,318.02 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,847.39 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $1,596.09 | 2021-2025 | Saphnelo |
| Amgen INC. | $1,589.41 | 2021-2025 | Evenity, Enbrel, Otezla |
| Genzyme Corporation | $1,216.70 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $637.08 | 2021-2025 | |
| Lilly USA, LLC | $629.18 | 2021-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $508.06 | 2021-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $427.53 | 2022-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $424.21 | 2021-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.50 | 2021-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $304.63 | 2022-2023 | Krystexxa |
| Sandoz INC. | $216.47 | 2023-2025 | Hyrimoz |
| Fresenius Kabi USA, LLC | $194.50 | 2023-2025 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $194.27 | 2022-2025 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $173.30 | 2022-2024 | Uptravi, Opsumit |
| Pfizer INC. | $154.61 | 2022-2025 | |
| Genentech USA, INC. | $85.81 | 2023 | Actemra |
| Organon LLC | $75.89 | 2023-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $74.66 | 2022-2023 | Purified Cortrophin Gel |
| Radius Health, INC. | $53.21 | 2021-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $52.05 | 2024-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $38.86 | 2024 | Acthar |
| Mylan Institutional INC. | $18.47 | 2023 | Hulio |
| Tonix Medicines, INC. | $13.94 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Oblander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.